Goiter medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Goiter}} | {{Goiter}} | ||
{{CMG}}; {{AE}}{{ARK}} | {{CMG}}; {{AE}}{{ARK}} {{MJ}} | ||
==Overview== | ==Overview== | ||
| Line 35: | Line 35: | ||
**It also decreases [[vascularity]]. | **It also decreases [[vascularity]]. | ||
*The following table summarizes the medical therapy and surgical option for treatment.<SMALL> | *The following table summarizes the medical therapy and surgical option for treatment. | ||
<SMALL> | |||
{| class="wikitable" | |||
!Treatment | |||
!Mechanism | |||
!Route of administration | |||
!Advantages | |||
!Disadvantages | |||
!Special considerations | |||
|- | |||
|Beta-blockers | |||
| | |||
* Block β-adrenergic receptors; | * Block β-adrenergic receptors; | ||
* propranolol may block conversion of T4 to T3 | * propranolol may block conversion of T4 to T3 | ||
|Oral; may be administered | |||
intravenously in acute | |||
cases | |||
|Ameliorates sweating, anxiety, tremulousness, palpitations, and tachycardia | |||
| | |||
* Does not influence course of disease | * Does not influence course of disease | ||
* Use cautiously in patients with asthma, CHF , bradyarrhythmias or Raynaud’s phenomenon | * Use cautiously in patients with asthma, CHF , bradyarrhythmias or Raynaud’s phenomenon | ||
| | |||
* Use cardioselective beta-blockers, especially in patients with COPD | * Use cardioselective beta-blockers, especially in patients with COPD | ||
* Use calcium-channel blockers as alternative | * Use calcium-channel blockers as alternative | ||
|- | |||
|Antithyroid drugs ([[methimazole]], | |||
[[carbimazole]], | |||
and [[propylthiouracil]]) | |||
| | |||
* Methimazole, carbimazole, and propylthiouracil block thyroid peroxidase and thyroid hormone synthesis | * Methimazole, carbimazole, and propylthiouracil block thyroid peroxidase and thyroid hormone synthesis | ||
* propylthiouracil also blocks conversion of thyroxine to triiodothyronine | * propylthiouracil also blocks conversion of thyroxine to triiodothyronine | ||
|Given as either a single, high fixed dose (e.g., 10–30 mg of methimazole or 200–600 mg of propylthiouracil daily) | |||
and adjusted as euthyroidism is achieved or combined with thyroxine to prevent hypothyroidism (“block–replace” regimen) | |||
| | |||
* Outpatient therapy | * Outpatient therapy | ||
* Low risk of hypothyroidism | * Low risk of hypothyroidism | ||
* No radiation hazard or surgical risk | * No radiation hazard or surgical risk | ||
* Remission rate 40–50% | * Remission rate 40–50% | ||
| | |||
* High recurrence rate | * High recurrence rate | ||
* Frequent testing required unless block-replacement therapy is used | * Frequent testing required unless block-replacement therapy is used | ||
* Minor side effects in ≤5% of patients (rash, urticaria, arthralgia, fever, nausea, abnormalities of taste and smell) | * Minor side effects in ≤5% of patients (rash, urticaria, arthralgia, fever, nausea, abnormalities of taste and smell) | ||
|Major side effect usually within first 3 mo of therapy | |||
* Agranulocytosis in <0.2% of patients | * Agranulocytosis in <0.2% of patients | ||
* Hepatotoxicity in ≤0.1% | * Hepatotoxicity in ≤0.1% | ||
* Cholestasis for the thionamides and hepatocellular necrosis for propylthiouracil | * Cholestasis for the thionamides and hepatocellular necrosis for propylthiouracil | ||
* Antineutrophil cytoplasmic antibody–associated vasculitis in ≤0.1% of patients | * Antineutrophil cytoplasmic antibody–associated vasculitis in ≤0.1% of patients | ||
* Irradiation causes thyroid cell damage and cell death | |- | ||
|[[Iodine-131|Radioactive iodine]] | |||
(iodine-131) | |||
| | |||
* Irradiation causes thyroid cell damage and cell death | |||
|Oral; activity either fixed (e.g., 15 mCi [555 MBq]) or calculated on the basis of goiter size and uptake and turnover investigations | |||
| | |||
* Normally outpatient procedure | * Normally outpatient procedure | ||
* Definitive therapy | * Definitive therapy | ||
* Low cost | * Low cost | ||
* Few side effects | * Few side effects | ||
* Effectively reduces goiter size | * Effectively reduces goiter size | ||
| | |||
* Potential radiation hazards | * Potential radiation hazards | ||
* Adherence to a country’s particular radiation regulations | * Adherence to a country’s particular radiation regulations | ||
* Radiation thyroiditis | * Radiation thyroiditis | ||
* Decreasing efficacy with increasing goiter size | * Decreasing efficacy with increasing goiter size | ||
* Eventual hypothyroidism in most patients | * Eventual hypothyroidism in most patients | ||
| | |||
* Should not be used in patients with active thyroid ophthalmopathy | * Should not be used in patients with active thyroid ophthalmopathy | ||
* Contraindicated in women who are pregnant or breast-feeding and for 6 wk after breast-feeding has stopped | * Contraindicated in women who are pregnant or breast-feeding and for 6 wk after breast-feeding has stopped | ||
|- | |||
|Thyroidectomy | |||
|Most or all thyroid tissue is removed surgically | |||
| ----- | |||
| | |||
* Rapid euthyroidism | * Rapid euthyroidism | ||
* Recurrence extremely rare | * Recurrence extremely rare | ||
| Line 76: | Line 121: | ||
* No radiation hazard, | * No radiation hazard, | ||
* Definitive histologic results | * Definitive histologic results | ||
* Rapid relief of pressure symptoms | * Rapid relief of pressure symptoms | ||
| | |||
* Most expensive therapy | * Most expensive therapy | ||
* Hypothyroidism is the aim | * Hypothyroidism is the aim | ||
* Risks associated with surgery and anesthesiology | * Risks associated with surgery and anesthesiology | ||
* Minor complications in 1–2% of patients (bleeding, infection, scarring), | * Minor complications in 1–2% of patients (bleeding, infection, scarring), | ||
* Major complications in 1–4% (hypoparathyroidism, recurrent laryngeal-nerve damage) | * Major complications in 1–4% (hypoparathyroidism, recurrent laryngeal-nerve damage) | ||
| | |||
* Does not influence course of Graves’ ophthalmopathy during pregnancy | * Does not influence course of Graves’ ophthalmopathy during pregnancy | ||
* Is best performed during the second trimester | * Is best performed during the second trimester | ||
|} | |||
</SMALL> | |||
==References== | ==References== | ||
Latest revision as of 19:51, 20 November 2017
|
Goiter Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Goiter medical therapy On the Web |
|
American Roentgen Ray Society Images of Goiter medical therapy |
|
Risk calculators and risk factors for Goiter medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2] Mehrian Jafarizade, M.D [3]
Overview
Pharmacologic medical therapy for goiter involves normalizing thyroid hormone levels and treating the inflammation. Treatment regimen involves Lugol's iodine, antithyroid drugs and β-adrenergic blockers. In some cases, radioactive iodine may be used to treat an overactive thyroid gland.
Medical Therapy
- Pharmacologic medical therapy is recommended for patients with goiter. [1][2][3][4][5][6][7][8][9][10][11][12][13][14]
Hypothyroidism:
- In cases of hypothyroidism, thyroid hormone replacement with levothyroxine may help resolve symptoms of hypothyroidism and also help with the slow release of thyroid stimulating hormone (TSH) from pituitary which would result in the decrease in the size of the goiter.
- The drug used in the treatment of hypothyroidism is:
- Levothyroxine:
- Lifelong synthetic levothyroxine (L-T4) is used to treat the hypothyroidism.
- Main goals of levothyroxine replacement therapy are:
- Resolution of the hypothyroid symptoms and signs including biological and physiologic markers of hypothyroidism,
- Normalization of serum thyrotropin with improvement in thyroid hormone concentrations,
- To avoid overtreatment (iatrogenic thyrotoxicosis).
- Side effects include atrial fibrillation and osteoporosis. Drug Regimen:
- Synthetic levothyroxine (L-T4) 1.6–1.8 μg/kg of body weight per day orally.
- Levothyroxine:
Hyperthyroidism:
- In hyperthyroidism, treatment targeted at normalizing thyroid hormone levels is considered.
- In cases of inflammation of thyroid gland, medication to treat the inflammation are generally prescribed. For goiters associated with hyperthyroidism, you may need medications to normalize thyroid hormone levels.
- Radioactive Iodine: In some cases, radioactive iodine may be used to treat an overactive thyroid gland. Radioactive iodine is prescribed as an oral medication which helps destroy thyroid cells resulting in the decreasing the size of the goiter. This therapy may also lead to under-activity of the thyroid gland.
- Lugol's iodine:
- Decreases thyroid hormone synthesis,
- Decreases vascularity.
- Antithyroid drugs such as carbimazole, methimazole:
- Used to restore the patient to a euthyroid state
- β-adrenergic blockers such as propranolol:
- Lowers tachycardia and palpitations,
- Used to restore the patient to a euthyroid state,
- It also decreases vascularity.
- The following table summarizes the medical therapy and surgical option for treatment.
| Treatment | Mechanism | Route of administration | Advantages | Disadvantages | Special considerations |
|---|---|---|---|---|---|
| Beta-blockers |
|
Oral; may be administered
intravenously in acute cases |
Ameliorates sweating, anxiety, tremulousness, palpitations, and tachycardia |
|
|
| Antithyroid drugs (methimazole,
carbimazole, and propylthiouracil) |
|
Given as either a single, high fixed dose (e.g., 10–30 mg of methimazole or 200–600 mg of propylthiouracil daily)
and adjusted as euthyroidism is achieved or combined with thyroxine to prevent hypothyroidism (“block–replace” regimen) |
|
|
Major side effect usually within first 3 mo of therapy
|
| Radioactive iodine
(iodine-131) |
|
Oral; activity either fixed (e.g., 15 mCi [555 MBq]) or calculated on the basis of goiter size and uptake and turnover investigations |
|
|
|
| Thyroidectomy | Most or all thyroid tissue is removed surgically | ----- |
|
|
|
References
- ↑ Astwood, E. B. (1960). "Treatment of Goiter and Thyroid Nodules with Thyroid". JAMA. 174 (5): 459. doi:10.1001/jama.1960.03030050001001. ISSN 0098-7484.
- ↑ Sawin CT, Geller A, Hershman JM, Castelli W, Bacharach P (1989). "The aging thyroid. The use of thyroid hormone in older persons". JAMA. 261 (18): 2653–5. PMID 2709545.
- ↑ Sawin, Clark T. (1989). "The Aging Thyroid". JAMA. 261 (18): 2653. doi:10.1001/jama.1989.03420180077034. ISSN 0098-7484.
- ↑ Führer D, Bockisch A, Schmid KW (2012). "Euthyroid goiter with and without nodules--diagnosis and treatment". Dtsch Arztebl Int. 109 (29–30): 506–15, quiz 516. doi:10.3238/arztebl.2012.0506. PMC 3441105. PMID 23008749.
- ↑ Baskin, H. Jack; Cobin, Rhoda H.; Duick, Daniel S.; Gharib, Hossein; Guttler, Richard B.; Kaplan, Michael M.; Segal, Robert L.; Garber, Jeffrey R.; Hamilton, Carlos R.; Handelsman, Yehuda; Hellman, Richard; Kukora, John S.; Levy, Philip; Palumbo, Pasquale J.; Petak, Steven M.; Rettinger, Herbert I.; Rodbard, Helena W.; Service, F. John; Shankar, Talla P.; Stoffer, Sheldon S.; Tourtelot, John B. (2002). "AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE EVALUATION AND TREATMENT OF HYPERTHYROIDISM AND HYPOTHYROIDISM". Endocrine Practice. 8 (6): 457–469. doi:10.4158/1934-2403-8.6.457. ISSN 1530-891X.
- ↑ Wesche, Maria F. T.; Tiel-v Buul, Monique M. C.; Lips, Paul; Smits, Nico J.; Wiersinga, Wilmar M. (2001). "A Randomized Trial Comparing Levothyroxine with Radioactive Iodine in the Treatment of Sporadic Nontoxic Goiter". The Journal of Clinical Endocrinology & Metabolism. 86 (3): 998–1005. doi:10.1210/jcem.86.3.7244. ISSN 0021-972X.
- ↑ Bonnema, Steen J.; Bertelsen, Henrik; Mortensen, Jesper; Andersen, Peter B.; Knudsen, Dorthe U.; Bastholt, Lars; Hegedüs, Laszlo (1999). "The Feasibility of High Dose Iodine 131 Treatment as an Alternative to Surgery in Patients with a Very Large Goiter: Effect on Thyroid Function and Size and Pulmonary Function1". The Journal of Clinical Endocrinology & Metabolism. 84 (10): 3636–3641. doi:10.1210/jcem.84.10.6052. ISSN 0021-972X.
- ↑ Nygaard, Birte; Knudsen, Jens Helmer; Hegedüs, Laszlo; Scient, Annegrete Veje Cand; Mølholm Hansen, Jens Erik (1997). "Thyrotropin Receptor Antibodies and Graves' Disease, a Side-Effect of131I Treatment in Patients with Nontoxic Goiter1". The Journal of Clinical Endocrinology & Metabolism. 82 (9): 2926–2930. doi:10.1210/jcem.82.9.4227. ISSN 0021-972X.
- ↑ Greer, Monte A.; Astwood, E. B. (1953). "TREATMENT OF SIMPLE GOITER WITH THYROID*". The Journal of Clinical Endocrinology & Metabolism. 13 (11): 1312–1331. doi:10.1210/jcem-13-11-1312. ISSN 0021-972X.
- ↑ Squatrito, S.; Vigneri, R.; Rybello, F.; Ermans, A. M.; Polley, R. D.; Ingbar, S. H. (1986). "Prevention and Treatment of Endemic Iodine-Deficiency Goiter by Iodination of a Municipal Water Supply*". The Journal of Clinical Endocrinology & Metabolism. 63 (2): 368–375. doi:10.1210/jcem-63-2-368. ISSN 0021-972X.
- ↑ Hegedüs, Laszlo; Bonnema, Steen J. (2010). "Approach to Management of the Patient with Primary or Secondary Intrathoracic Goiter". The Journal of Clinical Endocrinology & Metabolism. 95 (12): 5155–5162. doi:10.1210/jc.2010-1638. ISSN 0021-972X.
- ↑ Haines, Samuel F.; Keating, F. Raymond; Power, Marschelle H.; Williams, Marvin M. D.; Kelsey, Mavis P. (1948). "THE USE OF RADIOIODINE IN THE TREATMENT OF EXOPHTHALMIC GOITER*". The Journal of Clinical Endocrinology & Metabolism. 8 (10): 813–825. doi:10.1210/jcem-8-10-813. ISSN 0021-972X.
- ↑ Reveno, William S. (1948). "PROPYLTHIOURACIL IN THE TREATMENT OF TOXIC GOITER". The Journal of Clinical Endocrinology & Metabolism. 8 (10): 866–874. doi:10.1210/jcem-8-10-866. ISSN 0021-972X.
- ↑ Brenta, G.; Schnitman, M.; Fretes, O.; Facco, E.; Gurfinkel, M.; Damilano, S.; Pacenza, N.; Blanco, A.; Gonzalez, E.; Pisarev, M. A. (2003). "Comparative Efficacy and Side Effects of the Treatment of Euthyroid Goiter with Levo-Thyroxine or Triiodothyroacetic Acid". The Journal of Clinical Endocrinology & Metabolism. 88 (11): 5287–5292. doi:10.1210/jc.2003-030095. ISSN 0021-972X.